US FDA panel recommends approval of Johnson & Johnson’s depression drug


An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson’s experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

Share this content

Share on Facebook
Share on Twitter
Share via E-Mail

REUTERS: An advisory panel to the U.S. Food and Drug Administration on Tuesday recommended Johnson & Johnson’s experimental nasal spray, which has a compound similar to often-abused ketamine, for patients suffering from depression.

The panel voted 14-2 in favor of the drug esketamine, developed to treat major depression in patients who have not benefited from at least two different therapies, saying its benefits outweighed the risks.

One member in the panel abstained from voting on the question.

Esketamine is a variation of the anesthetic ketamine, which is also abused as a recreational party drug with the street nickname Special K.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta)

…read more

Source:: Daily times

      

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *